<DOC>
	<DOCNO>NCT00499668</DOCNO>
	<brief_summary>RATIONALE : Antiemetic drug , aprepitant ondansetron , may help lessen nausea vomit caused opioids . It yet know whether aprepitant effective ondansetron treat nausea vomit caused opioids patient cancer . PURPOSE : This randomized clinical trial study aprepitant see well work compare ondansetron treat nausea vomit caused opioids patient cancer .</brief_summary>
	<brief_title>Aprepitant Ondansetron Treating Nausea Vomiting Caused By Opioids Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy aprepitant monotherapy opioid-induced nausea vomiting ( OINV ) comparison ondansetron hydrochloride patient fail least one prior anti-emetic agent/regimen . Secondary - To determine whether control OINV improve quality life . - To determine control OINV decrease pain . - To determine control OINV improve mood . OUTLINE : Patients randomize 1 2 treatment arm . - Arm A : Patients receive aprepitant orally daily 7 day absence unacceptable toxicity persistent grade 4 nausea vomiting . - Arm B : Patients receive ondansetron hydrochloride orally 3 time daily 7 day absence unacceptable toxicity persistent grade 4 nausea vomiting . Patients complete follow questionnaire : Functional Assessment Cancer Therapy-General ( FACT-G ) ; Center Epidemiologic Studies Depression Scale ( CES-D ) ; Brief Pain Index ( BPI ) baseline day 7 . Patients also complete symptom diary document follow : number episode ( emetic episode define simple vomit retch , number continuous vomit retch ; distinct episode separate least 1 minute ) vomit retch include date time ; bad average degree nausea ( record every 2 hour awake first 24 hour treatment every 8 hour day 1-7 ) ; adverse event episodes vomit nausea .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : History malignancy ( include hematological malignancy ) Has pain require opioid analgesic Nausea vomiting ( associate opioid analgesic use ) unrelieved least one standard antiemetic regimen ( include 5HT3 antagonist dexamethasone combination therapy ) Patients fail ondansetron hydrochloride treatment opioidinduced nausea vomiting exclude study PATIENT CHARACTERISTICS : ECOG performance status 02 Able assess severity nausea vomit document diary Women must pregnant lactate Women childbearing potential sexually active male strongly advise use accept effective method contraception Urine pregnancy test give woman childbearing age No concern compliance medication regimen medical followup ( patient must able tolerate oral dose ) No severe chronic illness cause nausea vomiting , judgment treat physician , place patient risk No severe gastrointestinal obstruction active peptic ulcer disease Serum ALT AST &lt; 2 time upper limit normal ( ULN ) Serum bilirubin &lt; 2 time ULN Serum alkaline phosphatase &lt; 2 time ULN PRIOR CONCURRENT THERAPY : No surgery within past 7 day No chemotherapy within past 7 day No total low body radiation therapy within past 7 day Patient may schedule undergo total body irradiation lower body irradiation , chemotherapy , surgery study participation Patient must take warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>nausea vomit</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>adult T-cell leukemia/lymphoma</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>hairy cell leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>AIDS-related lymphoma</keyword>
	<keyword>adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>adult Burkitt lymphoma</keyword>
	<keyword>adult diffuse large cell lymphoma</keyword>
	<keyword>adult diffuse mixed cell lymphoma</keyword>
	<keyword>adult diffuse small cleave cell lymphoma</keyword>
	<keyword>adult immunoblastic large cell lymphoma</keyword>
	<keyword>adult lymphoblastic lymphoma</keyword>
	<keyword>grade 1 follicular lymphoma</keyword>
	<keyword>grade 2 follicular lymphoma</keyword>
	<keyword>grade 3 follicular lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>multiple myeloma plasma cell neoplasm</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>chronic myeloproliferative disorder</keyword>
	<keyword>myelodysplastic/myeloproliferative disease</keyword>
</DOC>